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INTRODUCTION
Head and neck squamous cell carcinoma (HNSCC) ac-
counts for nearly 10% of all malignancies, and paranasal 
sinus and nasal cavity (PNSNC) neoplasms represent 3% 
of head and neck malignancies [1,2]. Although tumors 
of the PNSNC are relatively rare, treatment planning 
for cancer of the PNSNC is challenging because of its 
heterogenous behavior and proximity to vital structures 
such as the orbit, skull base, and brain. Historically, the 
preferred treatment for tumors of the PNSNC, as well as 
HNSCC of other sites, consisted of en bloc resection of 
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Background/Aims: The role of induction chemotherapy (IC) for eyeball preser-
vation has not been established in head and neck squamous cell carcinoma (HN-
SCC) of the paranasal sinus and nasal cavity (PNSNC). Periorbital involvement 
frequently leads to eyeball exenteration with a margin of safety. We evaluated the 
treatment outcomes, including survival and eyeball preservation, of patients who 
received IC for HNSCC of the PNSNC.
Methods: We reviewed 21 patients diagnosed with HNSCC of the PNSNC who 
were treated with IC. We analyzed response, eyeball preservation rate, and overall 
survival.
Results: Tumors were located in the paranasal sinus (n = 14) or nasal cavity (n = 7). 
Most patients had stage T4a (n = 10) or T4b (n = 7) disease. More than half of the 
patients received a chemotherapy regimen of docetaxel, fluorouracil, and cisplatin 
(n = 11). Thirteen patients (61.9%) achieved a partial response after IC and 15 pa-
tients (71.4%) achieved T down-staging. Among 17 patients with stage T4 disease, 
which confers a high risk of orbital exenteration, 14 (82.4%) achieved preservation 
of the involved eye. The 3-year overall survival (OS) rate of patients who achieved 
a partial response to IC was 84.6%. The 3-year OS rate of patients with stable dis-
ease or disease progression after IC was 25.0% (p = 0.038).
Conclusions: IC could be considered for down-staging patients with advanced 
T-stage disease. It could also be a reasonable option for eyeball preservation in lo-
cally advanced HNSCC of the PNSNC.
Keywords: Induction chemotherapy; Head and neck neoplasms; Paranasal sinus-
es; Nasal cavity; Orbit evisceration
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the primary tumor. This method has been replaced by 
less-invasive but equally effective treatments such as de-
finitive radiotherapy and concurrent chemoradiothera-
py (CCRT) [3-6]. Despite the availability of such advanced 
modalities, the overall survival (OS) rate of HNSCC of 
the PNSNC has not improved and the 5-year surviv-
al rate has remained approximately 40% to 50% [7-10]. 
Moreover, the risk of orbital invasion and the need for 
eyeball exenteration represent extreme deterioration of 
quality of life for patients with HNSCC of the PNSNC. 
Approximately 12% to 40% of patients with locally ad-
vanced HNSCC of the PNSNC eventually undergo eye-
ball exenteration [11-14].
The benefits of induction chemotherapy were first 
noted from evidence that suggested that chemotherapy 
improved the organ preservation rate and reduced dis-
tant metastasis in laryngeal cancer [15,16]. Although most 
studies of induction chemotherapy in HNSCC have fo-
cused on larynx preservation, some attempts have been 
made to establish the effects of induction chemotherapy 
on eyeball preservation in cancer of the PNSNC, which 
confers a high risk of orbital invasion. To date, encour-
aging organ preservation rates have been reported [17-
19], but actual orbital preservation rates could be better 
than reported since the most effective chemotherapy 
regimen was not used in these previous studies; the reg-
imen of docetaxel, cisplatin, and fluorouracil, which is 
more effective than previous regimens, is now the stan-
dard of care and is used frequently [20-22]. We previous-
ly reported treatment outcomes of definitive radiother-
apy in patients diagnosed with HNSCC of the PNSNC 
at Seoul National University Hospital (SNUH) and we 
showed that patients treated with induction chemother-
apy had favorable OS compared to those who were not 
treated with chemotherapy (p = 0.037) [23]. In a recent ret-
rospective study of induction chemotherapy containing 
a taxane and platinum in HNSCC of the PNSNC, 67% of 
patients achieved at least a partial response and only six 
out of 46 patients failed to preserve the involved eye [24]. 
These findings imply that adequate induction chemo-
therapy can save the involved eye in patients with orbital 
invasion.
The purpose of the current study was to evaluate the 
role of induction chemotherapy in locally advanced 




We retrospectively reviewed medical records of patients 
who were diagnosed with HNSCC of the PNSNC who 
were treated at SNUH from August 2005 to March 2012. 
For the analysis, we included adult patients aged 18 
years or older with primary squamous carcinoma of the 
PNSNC who were treated with induction chemothera-
py. Other inclusion criteria included having more than 
one measurable lesion according to the response evalu-
ation criteria in solid tumours (RECIST) 1.1 [25]; an Easte-
ern Cooperative Oncology Group performance status 
(ECOG PS) of 0 to 2; and adequate hematologic, hepatic, 
and renal functions. We analyzed the following variables 
during a review of the medical records of included pa-
tients: sex; diagnosis date; age; ECOG PS; history of oth-
er malignancies; tumor location; TNM stage according 
to the American Joint Committee on Cancer Staging 
Manual, 7th edition, which defined stage T3 as a tumor 
invading the orbital floor, stage T4a as a tumor invading 
the orbital contents, and stage T4b as a tumor invad-
ing the orbital apex [26]; induction regimen; induction 
response; whether a salvage operation was performed; 
whether the eyeball was preserved; and the date of last 
follow-up or death.
Treatment
The treatment modality was decided by a multidis-
ciplinary team. Bulky nodal status, advanced T- or 
N-stage, and the possibility of eyeball preservation af-
ter induction chemotherapy influenced the treatment 
decision. Induction chemotherapy was cycled every 3 
weeks and induction regimens included docetaxel, cis-
platin, and fluorouracil. Following induction chemo-
therapy, patients received definitive treatment such as 
CCRT, radiotherapy alone, and operation. CCRT regi-
mens consisted of conventional standard fractionated 
radiotherapy of more than 60 Gy for primary tumor and 
regional lymph nodes, with concurrent chemotherapy 
with weekly administration of cisplatin 35 mg/m2.
Response evaluation and outcome measurement
We assessed complete physical examinations and all 
imaging studies, including magnetic resonance images 
or computed tomography of the head and neck, for all 
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patients. Follow-up imaging was performed after two 
(n = 8) or three (n = 13) cycles of induction chemother-
apy and responses were evaluated according to RECIST 
version 1.1 [25]. T down-staging was defined as a reducfi-
tion of T-stage from T4b to T4a or T4a to a lower stage. 
The primary objective of our study was to quantify the 
eyeball preservation rate and OS according to response 
to induction chemotherapy. Eyeball preservation was 
defined as eyeball function that was not disrupted by 
salvage operation, including eyeball exenteration, or 
progression of an inoperable tumor. A tumor was deter-
mined to be inoperable by a multidisciplinary team that 
included surgeons and radiologists [11-14]. Follow-up 
imaging was performed at 4 to 8 weeks after the end 
of definitive treatment, then every 3 to 6 months until 
progression or death. OS was measured from the date 
of diagnosis until death or the date of last follow-up, if 
censored.
Safety and compliance assessment
Adverse events were monitored and recorded every cy-
cle of induction chemotherapy according to Common 
Terminology Criteria for Adverse Events version 3.0. 
Compliance of definitive treatment of CCRT or RT was 
defined as good if patient received more than 90% of 
pre-planned dose of radiotherapy.
Statistical analysis
We used the chi-square test to determine the associa-
tions between response to chemotherapy and clinico-
pathologic parameters. We also conducted Kaplan-Mei-
er estimates and Cox regression analyses of OS. Results 
were considered significant when p values were less than 
0.05. Analyses were completed with STATA software ver-
sion 12 (StataCorp LP, College Station, TX, USA). 
Ethics
The study protocol was approved by the Institutional 
Review Board of SNUH (approval number: H-1307-051-
504) and was conducted in accordance with the Princi-
ples of the Declaration of Helsinki.
RESULTS
Patient characteristics
Baseline characteristics of patients are listed in Table 1. 
The median follow-up duration was 83.1 months (range, 
28.8 to 109.1). The median age was 57 years (range, 24 
to 75) and 15 of the patients (71.4%) were male. Tumors 
were located in the paranasal sinus (n = 14) or the na-
sal cavity (n = 7). Most patients had stage T4a (n = 10) 
or T4b (n = 7) disease. Induction chemotherapy regi-
mens were docetaxel plus flourouracil plus cisplatin (n 
= 11), docetaxel plus flourouracil (n = 8), and docetaxel 
plus cisplatin (n = 2). Fifteen patients (71.4%) received 
three cycles of induction chemotherapy and six patients 
(28.6%) received two cycles. Mean cycle of induction che-
motherapy was 2.7. Thirteen patients (61.9%) achieved a 
partial response after induction chemotherapy and 15 
patients (71.4%) achieved T down-staging. Toxicity pro-
file during induction chemotherapy was summarized 
in Table 2. Overall, induction chemotherapy was tol-
erable with except nausea and neutropenia (grade 3 or 
4: 14.3% and 9.5%, respectively). Sixteen patients (76.2%) 
tolerated full-dose of induction chemotherapy, but four 
patients (19%) and one patient (4.8%) had 80% and 75% 
of pre-planned dose, respectively. However, all patients 
had good compliance during the definitive treatment of 
CCRT or RT.
After induction chemotherapy, 14 patients underwent 
definitive radiotherapy either with concurrent chemo-
therapy with weekly administration of cisplatin (n = 11) 
or radiotherapy alone (n = 3). Six patients underwent a 
salvage operation and one patient was lost to follow-up 
after induction chemotherapy.
Patients who achieved either stable disease or pro-
gressive disease after induction chemotherapy were old-
er, had higher T-stages, and received more salvage oper-
ations than patients who achieved a partial response, but 
these differences were not statistically significant. All 
patients who achieved a partial response also achieved 
T down-staging and eyeball preservation. Six out of 
eight patients with stable or progressive disease did not 
achieve T down-staging, and three patients eventually 
lost an eyeball during the follow-up period.
Eyeball preservation after induction chemotherapy
Patients with HNSCC of the PNSNC who had stage T4a 
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Table 1. Patient characteristics
Characteristic All (n = 21) Induction PR (n = 13) Induction SD/PD (n = 8) p value
Age, yr 57 (24–75) 56 (24–73) 61 (50–75) 0.282
Male sex 15 (71.4) 8 (61.5) 7 (87.5) 0.201
ECOG PS
0  7 (33.3) 3 (23.1) 4 (50.0)
1  12 (57.1) 8 (61.5) 4 (50.0)
2 2 (9.5) 2 (15.4) 0 0.298
T-stage
1 1 (4.7) 1 (7.7) 0  
2 0 0 0
3 3 (14.3) 3 (23.1) 0  
4a 10 (47.6) 4 (30.8) 6 (75.0)
4b 7 (33.3) 5 (38.5) 2 (25.0) 0.190
N-stage
0 14 (66.7) 9 (69.2) 5 (62.5)
1 3 (14.3) 2 (15.4) 1 (12.5)
2 4 (19.1) 2 (15.4) 2 (25.0) 0.859
Stage
III 3 (14.3) 3 (23.1) 0
IV 18 (85.7) 10 (76.9) 8 (100.0) 0.142
Tumor location
Paranasal sinus 14 (66.7) 9 (69.2) 5 (62.5)
Nasal cavity 7 (33.3) 4 (30.8) 3 (37.5) 0.751
Induction chemotherapy regimen
DFP 11 (52.4) 7 (53.9) 4 (50.0)
FP 8 (38.1) 5 (38.5) 3 (37.5)
DP 2 (9.5) 1 (7.7) 1 (12.5) 0.935
Induction chemotherapy response
CR 0 0 0
PR 13 (61.9)  13 (100.0) 0
SD 6 (28.6) 0 6 (75.0)
PD 2 (9.5) 0 2 (25.0) < 0.001a
T down-staging
Yes 15 (71.4) 13 (100.0) 2 (25.0)
No 6 (28.6) 0 6 (75.0) <0.001a
Definitive treatment
CCRT 11 (52.4) 7 (53.9) 4 (50.0)
Radiotherapy 3 (14.3) 1 (7.7) 2 (25.0)
Operationb 6 (28.5) 4 (30.8) 2 (25.0)
No treatment 1 (4.8) 1 (7.7) 0 0.631
Salvage operationc
Yes 10 (47.6) 5 (38.5) 5 (62.5)
No 11 (52.4) 8 (61.5) 3 (37.5) 0.284
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or T4b disease were at risk of orbital penetration [13,14]. 
All of the patients who had a T-stage lower than T4 (n = 
4) preserved their eyeballs after induction chemotherapy 
(Fig. 1). However, half of the patients (5 out of 10) with 
stage T4a disease required a salvage operation and two 
of these patients lost an eyeball: one underwent orbital 
exenteration and the other had a tumor that was inoper-
able due to massive invasion of the orbital cavity. More 
than half of the patients with stage T4b disease (4 out of 
7) also underwent a salvage operation; only one of these 
patients underwent orbital exenteration.
Survival according to response to induction chemo-
therapy
During the follow-up period, 3- and 5-year OS rates of 
patients with a partial response to induction chemother-
apy were 84.6% and 65.8%, respectively. In patients with 
stable or progressive disease, the 3- and 5-year OS rates 
were both 25% (p = 0.036) (Fig. 2A). Patients who achieved 
T down-staging had longer OS than those who did not 
achieve T down-staging (3-year OS, 80% vs. 16.7%; 5-year 
OS, 64% vs. 16.7%; p = 0.027) (Fig. 2B). OS according to 
stage and N-stage were graphed in Supplementary Fig. 
1. Patients with N-stage more than 1 had poorer OS than 
N0 disease (3-year OS, 71.4% vs. 42.9%; p = 0.031).
DISCUSSION
In the current study, we observed beneficial effects of 
induction chemotherapy in squamous cell carcinoma of 
the PNSNC on organ preservation and OS according to 
response to chemotherapy. Of the 21 patients included 
in our analysis, three patients who did not respond to 
induction chemotherapy eventually lost the involved 
eyeball. However, all patients who achieved a partial re-
sponse or T down-staging after induction chemothera-
py preserved the eyeball and achieved a favorable overall 
prognosis.
Although the role of induction chemotherapy has 
Characteristic All (n = 21) Induction PR (n = 13) Induction SD/PD (n = 8) p value
Eyeball preservation
Yes 18 (85.7) 13 (100.0) 5 (62.5)
No 3 (14.3) 0 3 (37.5) 0.017a
Values are presented as median (range) or number (%).
PR, partial response; SD, stable disease; PD, progressive disease; ECOG PS, Eastern Cooperative Oncology Group performance 
status; DFP, docetaxel plus fluorouracil plus cisplatin; FP, fluorouracil plus cisplatin; DP, docetaxel plus cisplatin; CR, com-
plete response; CCRT, concurrent chemoradiotherapy.
aValues indicate statistically significant correlations with p values less than 0.05.
bPatients assigned to surgical removal of tumor immediately after induction chemotherapy.
cPatients assigned to surgery immediately after induction chemotherapy or who needed salvage operation after definitive 
treatment with CCRT or radiotherapy.
Table 1. Continued
Table 2. Toxicity profile of induction chemotherapy
Grade 1 Grade 2 Grade 3 Grade 4
Nausea and vomiting 2 (9.5) 5 (23.8) 3 (14.3) 0
Diarrhea 0 3 (14.3) 0 0
Neuropathy 3 (14.3) 0 0 0
Neutropenia 0 2 (9.5) 2 (9.5) 0
Anemia 0 4 (19.0) 0 0
Thromcytopenia 1 (4.8) 0 0 0
Others 3 (14.3) 1 (4.8) 0 0
Values are presented as number (%). Grade of toxicity was referred from Common Terminology Criteria for Adverse Events 
(CTCAE) version 3.0.
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been well-established in organ preservation [15,16], the 
survival benefits from induction chemotherapy have 
been controversial in locally advanced HNSCC. Ran-
domized phase III trials that compared induction che-
motherapy before definitive CCRT and CCRT alone, 
which is the standard treatment regimen for locally 
advanced HNSCC, failed to show any survival benefits 
of adding induction chemotherapy [27-29]. Although a 
recent trial showed significant OS benefits of induction 
chemotherapy, the benefits were false positives since the 
survival benefits were abolished in patients who were as-
signed to cisplatin as the CCRT regimen and in patients 
with oropharyngeal cancer, which composed more than 
half of the cohort [30]. Considering the low incidence of 
tumors arising from the PNSNC, patients with PNSNC 
tumors were not included in previous studies and there 
have been no published prospective trials regarding the 
effects of induction chemotherapy on survival in HN-
SCC of the PNSNC. 
In the current study, we observed survival outcomes 
after induction chemotherapy in patients with tumors 
arising from the PNSNC. A total of 61.9% of patients 
achieved a partial response to induction chemotherapy 
and the 3-year OS rate of these patients was 84.6%. This 
result is comparable to results of a previous study, which 
showed a response rate of 67% and a 2-year OS rate of 
77% in patients who achieved either partial response 
or stable disease [24]. An important finding of the cur-
rent study is that all patients who achieved a partial 
response to induction chemotherapy were saved from 
orbital exenteration, which might have been required in 
patients with stage T4 disease (n = 9) if induction che-
motherapy had not been administered. However, eight 
out of 21 patients (38.1%) failed to achieve a partial re-
sponse to chemotherapy and the 3-year OS rate of these 
patients was significantly lower (25%) than patients who 
achieved a partial response. Additionally, these patients 
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Figure 2. Kaplan-Meier curves of patients according to response to induction chemotherapy (A) and T down-staging after 
induction chemotherapy (B). Numbers in the graph indicate the probability of survival at 3 years and at 5 years. HR, hazard ra-
tio; CI, confidence interval; ICT, induction chemotherapy; SD, stable disease; PD, progressive disease; PR, partial response; T 













3 CCRT without salvage op
1 Salvage op without ObE
4 CCRT without salvage op
 2 RT→consider salvage op
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1 Follow-up loss
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1 Inoperable, orbit loss
4  ≤ T3
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3 CCRT → salvage op
7 T4b
3 Salvage op without ObE
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Figure 1. Flow diagram of patients included in the study. Of 
17 patients with stage T4 disease, only three patients lost an 
eyeball during the follow-up period. CCRT, concurrent che-
mo radiotherapy; op, operation; ObE, orbital exenteration; 
RT, radiotherapy.
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exenteration (n = 2) or inoperable eyeball invasion (n = 
1). Previous reports have presented advances in surgical 
techniques and adjuvant radiotherapy that may improve 
eyeball preservation [31,32], but induction chemotherapy 
could be considered for increasing eyeball preservation 
rates in patients with advanced T-stage HNSCC of the 
PNSNC.
Previous trials have shown that patients who complete 
induction chemotherapy, as noted by an analysis of in-
tention-to-treat cohorts, benefit from chemotherapy 
[29]. Moreover, in a comparison of survival outcomes 
of adding induction chemotherapy to definitive CCRT 
in our institution, a subgroup analysis revealed that pa-
tients who achieved at least a partial response attained 
significant survival benefits compared to patients who 
received CCRT alone (unpublished). Therefore, it is im-
portant to select patients who would tolerate and benefit 
from induction chemotherapy. However, it is difficult to 
determine who would benefit from induction chemo-
therapy since we observed no significant differences in 
clinicopathologic characteristics between patients who 
achieved a partial response and patients with stable dis-
ease or progressive disease in the current study.
This study has several limitations. The small number 
of patients included in the analysis does not allow for sig-
nificant differences to be discerned between subgroups 
according to response to induction chemotherapy or 
orbital preservation. Moreover, the current study had a 
retrospective design, so the included patients might not 
be representative cases of all diagnosed patients. For ex-
ample, the cohort may have included a high number of 
healthy patients who tolerated induction chemotherapy, 
which might have resulted in better outcomes than ex-
pected. Nevertheless, considering the very low incidence 
of HNSCC of the PNSNC and the results of the current 
study, we conclude that induction chemotherapy may 
offer improved organ preservation and favorable surviv-
al. We focused on the effects of induction chemotherapy 
for this analysis, and the timing of salvage surgery and 
surgical techniques were not established. These factors 
might have affected the final outcomes of organ preser-
vation.
In conclusion, patients with HNSCC of the PNSNC, 
especially advanced T-stage disease, who responded to 
induction chemotherapy experienced increased rates of 
organ preservation and OS. Well-designed prospective 
trials are needed to establish the efficacy of induction 
chemotherapy in tumors arising from the PNSNC. 
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Supplementary Figure 1. Kaplan-Meier curves of patients according to initial stage (A) and N-stage (B). Numbers in the graph 
indicates probability of survival at 3 years and at 5 years. HR, hazard ratio; CI, confidence interval.
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